Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Daniel Mikol"'
Autor:
Todd Schwedt, Uwe Reuter, Stewart Tepper, Messoud Ashina, David Kudrow, Gregor Broessner, Guy P. Boudreau, Peter McAllister, Thuy Vu, Feng Zhang, Sunfa Cheng, Hernan Picard, Shihua Wen, Joseph Kahn, Jan Klatt, Daniel Mikol
Publikováno v:
The Journal of Headache and Pain, Vol 19, Iss 1, Pp 1-8 (2018)
Abstract Background Subcutaneous erenumab reduced monthly migraine days and increased the likelihood of achieving a ≥ 50% reduction at all monthly assessment points tested in 2 pivotal trials in episodic migraine (EM) and chronic migraine (CM). Ear
Externí odkaz:
https://doaj.org/article/09982463811948aaabfec9a3ebac8ce2
Autor:
Finn Sellebjerg, Diego Cadavid, Deborah Steiner, Luisa Maria Villar, Richard Reynolds, Daniel Mikol
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 9 (2016)
Multiple sclerosis (MS) is a common and chronic central nervous system (CNS) demyelinating disease and a leading cause of permanent disability. Patients most often present with a relapsing–remitting disease course, typically progressing over time t
Externí odkaz:
https://doaj.org/article/80a0cddbd63c4eeebdd5f2ea96d5ed77
Autor:
Ariane K, Kawata, Mary Kate, Ladd, Richard B, Lipton, Dawn C, Buse, Mark, Bensink, Shweta, Shah, Asha, Hareendran, Sally, Mannix, Daniel, Mikol
Publikováno v:
Headache: The Journal of Head and Face Pain. 62:159-168
The purpose of this study was to examine changes in the functional impact of migraine following treatment with erenumab, as measured by the Migraine Functional Impact Questionnaire (MFIQ).The MFIQ, a novel patient-reported outcome (PRO) measuring the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1614d3e4924d11344c8673eb6410fea5
https://doi.org/10.1111/head.14258
https://doi.org/10.1111/head.14258
Autor:
Mark Weatherall, Andreas Gantenbein, Shannon Ritter, Josefin Snellman, Jan Klatt Klatt, Daniel Mikol
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 93:A73.2-A73
ObjectiveErenumab is a fully human monoclonal antibody. Following a 12-wk double-blind (DB), placebo- controlled chronic migraine (CM) study, a 52-wk open-label extension (OLE) study assessed long-term efficacy and safety of erenumab. We report the l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::582a7a6d2326ff574e2215028dec9947
https://doi.org/10.1136/jnnp-2022-abn.237
https://doi.org/10.1136/jnnp-2022-abn.237
Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis
Autor:
Tatiana Plavina, Kumar Kandadi Muralidharan, Daniel Mikol, Meena Subramanyam, Sreeja Gopal, Geoffrey Kuesters, Ivan Nestorov
Publikováno v:
The Journal of Clinical Pharmacology. 57:1017-1030
Natalizumab (humanized immunoglobulin G4 antibody targeting alpha-4 integrins) is a highly efficacious treatment for relapsing-remitting multiple sclerosis (RRMS) that has been in clinical use since 2006. However, natalizumab pharmacokinetic (PK) cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65ebc40abe1d445c88c2c45f80123e38
https://doi.org/10.1002/jcph.894
https://doi.org/10.1002/jcph.894
Autor:
Sophia Lee, Daniel Mikol, Raj Kapoor, Jeffrey A. Cohen, Myla D. Goldman, Eva Havrdova, Douglas Jeffery, Hans-Peter Hartung, Aaron Miller, Shulian Shang, Deborah Kinch, Mark S. Freedman, Finn Sellebjerg, Diego Cadavid
Publikováno v:
Multiple Sclerosis Journal. 23:94-105
Background: The Expanded Disability Status Scale (EDSS) has wide scientific and regulatory precedent but limited ability to detect clinically relevant disability progression in secondary progressive multiple sclerosis (SPMS) patients, partly due to a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5ff7dfd6687798a6f5361d4ba0576d4
https://doi.org/10.1177/1352458516638941
https://doi.org/10.1177/1352458516638941
Autor:
Daniel Mikol, Ernst W. Radü, Ulrich Freudensprung, Hans-Peter Hartung, Ludwig Kappos, Yann Hyvert, Johan van Beek, Mark S. Freedman, Thomas Plitz, Marc Lamarine, Alexey Boyko
Publikováno v:
The Lancet Neurology. 13:353-363
Summary Background Depletion of B lymphocytes is associated with suppression of inflammatory activity in multiple sclerosis. We aimed to assess the safety and efficacy of atacicept, a recombinant fusion protein that suppresses B-cell function and ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a731ed358c544c5f29f4aa3de6077c2
https://doi.org/10.1016/s1474-4422(14)70028-6
https://doi.org/10.1016/s1474-4422(14)70028-6
Autor:
Diego Cadavid, Finn Sellebjerg, Daniel Mikol, Deborah Steiner, Richard Reynolds, Luisa M. Villar
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 9 (2016)
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Multiple sclerosis (MS) is a common and chronic central nervous system (CNS) demyelinating disease and a leading cause of permanent disability. Patients most often present with a relapsing–remitting disease course, typically progressing over time t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2510a37b2b5b9a82b1142d429d3c266c
https://pubmed.ncbi.nlm.nih.gov/26788129
https://pubmed.ncbi.nlm.nih.gov/26788129
Autor:
S. Naoshy, Daniel Mikol, Jennifer Petrillo, Jeremy Hobart, Sophie Cleanthous, Stefan J. Cano, D Steiner, Patrick Marquis, Crystal Watson
Publikováno v:
Value in Health. 18(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcdead191180e179b96984d81b3bcdbf
Publikováno v:
Journal of clinical pharmacology. 56(10)
The study's primary objective was to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of single subcutaneous (SC) or intramuscular (IM) 300-mg doses of natalizumab with IV 300-mg doses of natalizumab in patients with multiple sclerosis (MS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ec42c09f973b41ecaf173dcddba53a
https://pubmed.ncbi.nlm.nih.gov/26835603
https://pubmed.ncbi.nlm.nih.gov/26835603